Celecoxib doubles risk of

摘要

Treatment with celecoxib(Celebrex)doubles the risk of myocardial infarction compared with placebo,the authors of a meta-analysis suggest this week(Journal of the Royal Society of Medicine 2006;99:32).The researchers conducted a systematic review and meta-analysis of randomised double-blind clinical trials of at least six weeks' treatment with celecoxib and which presented data on serious cardiovascular thromboembolic events.Data from four trials involving 4,422 patients were examined.